James P. Boylan - 12 Sep 2024 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZBIO	Stock Option (Right to Buy)	Award	$0	+37,000		$0.000000	37,000	12 Sep 2024	Common Stock	37,000	$17.00	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Mr. Boylan has agreed to receive and hold for the benefit of, Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof.
F2	The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service.